Shinhan Securities Cuts Alteogen Target to ₩520,000 After Novartis AOC Phase 3 Failure — BigGo Finance
Shinhan Securities has lowered its target price for Alteogen from ₩540,000 (approximately $400) to ₩520,000 (approximately $390), following…